Cardiology
Latest News
Advertisement
Latest Videos
CME Content
Advertisement
More News
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The patient showed grade 4 liver transaminases and increased total bilirubin and was hospitalized.
In terms of safety, there were no AEs or serious AEs deemed related to AB-1002.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
In observance of World Heart Day, held annually on September 29, we took a look back at news in cell/gene therapy for cardiovascular disease from the past few months.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The trial, which is taking place in the United States, is expected to enroll 40 patients in total.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The hold was originally placed on the trial by the FDA on May 23, 2025, following the death of a patient treated in the study.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The company noted that it plans to submit the meeting request by the fourth quarter of this year and that the meeting will focus on the approvability of the product based on available clinical data.
Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
According to Rocket, the RMAT designation was granted based on results from a phase 1 clinical trial (NCT05885412).
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The CGTLive® team highlights 5 therapeutics that are nearing major decisions by the FDA.
Advertisement
Advertisement
Trending on CGTlive®
1
FDA Approves BMS’s Liso-Cel for R/R Marginal Zone Lymphoma
2
Autologous Stem Cell Therapy for Alzheimer Disease Advances to Phase 2 After Positive Early Findings
3
Key Unknowns Remain in Cell and Gene Therapy
4
Around the Helix: Cell and Gene Therapy Company Updates – December 3, 2025
5
